💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English

Efgartigimod Alfa

CHEMBL4297551 Phase 4 Approved Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A neonatal Fc receptor (FcRn) blocker that reduces the levels of harmful IgG antibodies in the blood, used to treat generalized myasthenia gravis. By lowering the antibodies that attack muscle receptors, it helps reduce muscle weakness.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A neonatal Fc receptor (FcRn) blocker that reduces the levels of harmful IgG antibodies in the blood, used to treat generalized myasthenia gravis. By lowering the antibodies that attack muscle receptors, it helps reduce muscle weakness.

Yes, Efgartigimod Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297551. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.